• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Broadens Criteria for Inclusion of Vulnerable Patients in Cancer Trials

FDA Broadens Criteria for Inclusion of Vulnerable Patients in Cancer Trials

July 13, 2020

Trials of oncology treatments should extend their inclusion criteria to encompass more vulnerable patient populations, the FDA says in four guidances it finalized last week.

Released as drafts in March 2019, the four guidances advise sponsors on inclusion criteria for pediatric patients, patients with brain metastases, those with organ dysfunction or other prior malignancies, and HIV and hepatitis patients (CenterWatch Weekly, March 18, 2019). The final documents are virtually unchanged from their drafts.

In addition to addressing pediatric inclusion in cancer trials, the FDA released a draft guidance in late June to help sponsors design pediatric trials of anti-infective drugs. Sponsors may extrapolate efficacy results from adult studies to use in pediatric studies, the draft guidance says, but still will need to gather safety and pharmacokinetics data to demonstrate that the proposed dosing regimen produces similar exposures in children and adults. Comments on the draft guidance are due by Aug. 29.

To read the guidance on inclusion of HIV and hepatitis patients in cancer trials, click here: https://bit.ly/2AMuQsm.

To read the guidance on including patients with organ dysfunction, click here: https://bit.ly/2ZWLUV7.

To read the guidance on brain metastases, click here: https://bit.ly/2DpblXK.

To read the guidance on including pediatric patients in cancer trials, click here: https://bit.ly/38VWikh.

To read the draft guidance on pediatric trials of anti-infective drugs, click here: https://bit.ly/3iTTdFZ.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing